Purdue, the company holding the patent for the drug, continued to market it as having low abuse potential, highlighting that patients needed to take fewer pills a day than with immediate-release formulations.
Purdue, kampuni inayoshikilia hataza ya dawa hiyo, iliendelea kuitangaza kuwa na uwezo mdogo wa matumizi mabaya, ikionyesha kwamba wagonjwa walihitaji kumeza vidonge vichache kwa siku kuliko viunda vinavyotolewa mara moja.